Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 0.44 |
| ▸ | MAOB | P27338 | 10/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409349 | 0.84 | MAOA (0.38) | MAOAMAOB | |
| SCHEMBL12408675 | 0.80 | MAOA (0.47) | MAOAMAOBKDM4EPOLBMAPT | |
| SCHEMBL12409387 | 0.78 | SPHK1 (0.36) | MAOAMAOB | |
| SCHEMBL12409577 | 0.78 | MAOA (0.45) | MAOAMAOBKDM4EPOLBMAPT | |
| SCHEMBL12375938 | 0.75 | MAOA (0.38) | MAOAMAOBKCNJ1 | |
| SCHEMBL12409336 | 0.74 | — | — | |
| SCHEMBL12410147 | 0.73 | MAOA (0.45) | MAOAMAOBKDM4EPOLBMAPT | |
| SCHEMBL12409370 | 0.72 | — | — | |
| SCHEMBL12409386 | 0.72 | MAOB (0.35) | MAOAMAOBKCNJ1 | |
| SCHEMBL12409975 | 0.72 | MAOB (0.37) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-08-11 | — | — | US | disclosed |
| US-7951305-B2 | Compound having hydrocoumarin skeleton, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090267026-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090267026-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | HCN2, PIEZO1, TRPV4 | MAOA 4598/4885MAOB 4652/4885KDM4E 3223/4885 |
| US-20110193021-A1 | COMPOUND HAVING HYDROCOUMARIN SKELETON, LIQUID CRYSTAL COMPOSTITION, AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, HCN2, HCN1 | MAOA 4053/4885MAOB 4167/4885KDM4E 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.